SEC Form 4 · accession 0001144204-17-011827
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Irit Arbel
Director
Period of report
Feb 26, 2017
Accepted (ET)
Feb 28, 2017 · 5:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 153,333 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.75 | Feb 26, 2017 | A | 6,667 | A | Feb 26, 2017 | Feb 26, 2027 | Common Stock | 6,667 | 6,667 | D |
Explanation of responses
- F1Represents shares of Common Stock previously acquired and reported on Form 3 or Form 4. As of the date of this filing Reporting Person beneficially owns 153,333 shares of Common Stock of the Issuer.
- F2Option is fully vested and exercisable on the date of grant.